Bracy Fertig is the CEO and Co-Founder of Orchestra Health Technologies Inc., a seed-stage healthcare technology promoting the use of precision medicine in oncology by optimizing the diagnostics pathway. Orchestra’s mission is to prevent late and mis-diagnosis, adding months to years to patients’ lives and saving the US healthcare system billions of dollars of spend on ineffective therapeutics.
Bracy is also venture partner at an emerging European growth-stage medtech and healthtech growth investor, focused on supporting portfolio companies with US expansion strategies.
Prior to her current role, Bracy began her career in medical research in the field of Biochemistry and Pharmacology. Her doctorate research focused on the targeting of the myofilament with protein therapeutics for the treatment of diastolic dysfunction in heart failure patients. Bracy founded an early-stage biotech company during her research career, focused on peptide-based therapeutics for heart failure. She subsequently moved onto a career in investment banking, where she build and led the healthcare practice at a London-based boutique investment and advisory firm, focusing primarily on digital health and medtech. In 2024, Bracy moved into technology, joining Caresyntax, a growth stage surgical technology company, as the Head of Strategy and Corporate Development. She also invests in healthcare technology and MedTech via a private family office, where she is Head of Platform and a member of the Investment Committee. From the United States originally, Bracy now lives in London.